1Kubota T,Andoh K,Sedakata H,et al.Tissue factor released from leukemuc cells [J].Thromb Haemostas,1991,65(1):59～63.
2Gordon SG,Benson B.Analysis of serum cancer procoagulant activity and its possibleuse as a tumor marker[J].Thromb Res,1989,56(3):431～440.
3Naschitz JE,Yeshurun D,Lev LM.Throm boembolism in cancer:changing trends[J].Cancer,1993,71(4):1384～1390.
4Lesrine MN.Prerention of thrombotic disorders in cancer pationts undergoing chemotherapy[J].Thromb Haemostas,1997,78(1):133～136.
5Kuaan HC,Keet HN. Fibrinolysis and cancer [J].Semin Thromb Hemost,1990,16(3):230～235.
6Neuland RJ,Haire WD.Elevated plasmiogen activator inhibitor levels found in patients with malignant conditions[J].Am J Clin Pathol,1991,96(5):602～604.
7Shen VS,Pollak EW.Fatal pulmonary embolism in cancer patients:is heparin prophyaxis justifid?[J].Southern Med J,1980,73(5):841～843.
8Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study[J]. J Thromb Haemost;2004,2(4) :619
9Fichtlscherer S,Breuer S, Heeschen C,et al. Interleukin--10 serum levels and systemic endothelial vas0reactivity in patients with coronary artery disease[J]. J Am Coil Cardiol, 2004;44 (1):44
10Roumen-- Klappe EM, den Heijer M, van Uum SH, et al. Inflammatory response in the acute phase of deep vein thrombosis [J]. J Vasc Surg,2002,35(4): 701
